NCT02614547View on ClinicalTrials.gov

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 15, 2015

Primary Completion Date

June 22, 2016

Study Completion Date

June 22, 2016

Conditions
Severe Postpartum Depression
Interventions
DRUG

SAGE-547

Administered as intravenous infusion.

DRUG

Placebo

Administered as intravenous infusion.

Trial Locations (4)

19104

Sage Investigational Site, Philadelphia

27514

Sage Investigational Site, Chapel Hill

30342

Sage Investigational Site, Atlanta

01655

Sage Investigational Site, Worcester

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT02614547 - A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression | Biotech Hunter | Biotech Hunter